	US 12,351,635 B2
	Pharmaceutical combinations comprising an anti-LY75 antibody
Monica Binaschi, Rome (IT); Mario Bigioni, Rome (IT); Giuseppe Merlino, Rome (IT); Cecilia Simonelli, Florence (IT); Francesco Bertoni, Bellinzona (CH); and Andrea Pellacani, Florence (IT)
Assigned to BERLIN-CHEMIE AG, Berlin (DE)
Filed by BERLIN-CHEMIE AG, Berlin (DE)
Filed on May 3, 2022, as Appl. No. 17/735,880.
Application 17/735,880 is a division of application No. 16/492,559, granted, now 11,365,258, previously published as PCT/EP2018/055939, filed on Mar. 9, 2018.
Claims priority of application No. 1703876 (GB), filed on Mar. 10, 2017.
Prior Publication US 2022/0289851 A1, Sep. 15, 2022
Int. Cl. A61P 35/00 (2006.01); A61K 31/519 (2006.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01)

CPC C07K 16/2851 (2013.01) [A61K 31/519 (2013.01); A61K 47/68033 (2023.08); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 16/2887 (2013.01)]

8 Claims

1. A pharmaceutical combination comprising:

(A) an anti-LY75 antibody, or an antigen-binding portion thereof, said antibody or portion thereof comprising:

a) a heavy chain variable region comprising:

i) a first vhCDR comprising SEQ ID NO: 5;

ii) a second vhCDR comprising SEQ ID NO: 6; and

iii) a third vhCDR comprising SEQ ID NO: 7; and

b) a light chain variable region comprising:

i) a first vlCDR comprising SEQ ID NO: 8;

ii) a second vlCDR comprising SEQ ID NO: 9; and

iii) a third vlCDR comprising SEQ ID NO: 10;

wherein the anti-LY75 antibody or antigen-binding portion thereof further comprises a covalently-attached drug, and wherein said drug is a maytansinoid or a derivative thereof and

(B) ibrutinib or a pharmaceutically-acceptable salt thereof,

wherein the pharmaceutical combination is in the form of a combined preparation for simultaneous, separate or sequential use.